- Sygnature Discovery receives Bronze rating from EcoVadis for sustainable practices.
- Initiatives include reducing carbon emissions, recycling waste, and participating in the International Laboratory Freezer Challenge.
![](https://pharmasource.global/wp-content/uploads/2024/04/sygnaturediscoveryfreezerchallenge-768x1024.png)
Sygnature Discovery, one of North America’s largest drug discovery Contract Research Organisations (CRO), has been recognised with the prestigious EcoVadis Award for Sustainable Excellence, achieving a Bronze rating from the globally respected sustainability ratings platform.
Over a three-year period, the company has implemented several initiatives aimed at reducing its environmental footprint. These include reducing carbon emissions in laboratory operations, recycling palladium waste, and transitioning to paperless invoicing. Furthermore, efforts to minimize energy usage are evident in the reduction of ultra-low temperature freezers.
One notable initiative is Sygnature Discovery’s active participation in the International Laboratory Freezer Challenge, organised by My Green Lab and the International Institute for Sustainable Laboratories (I2SL). This six-month challenge encourages efficient cold storage practices, aligning with the company’s commitment to sustainable procurement and environmental stewardship.
Dr Simon Hirst, CEO of Sygnature Discovery, emphasised the company’s dedication to setting the standard for sustainable excellence. He highlighted the importance of minimising environmental impact, promoting ethical conduct, and fostering social responsibility. The EcoVadis Bronze award, which places Sygnature Discovery in the top 35% of rated companies globally, reflects the company’s ongoing commitment to sustainability.